Arvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.
|Videos|November 21, 2014
Next-Generation Sequencing in Thyroid Cancer
Author(s)Marcia S. Brose, MD, PhD, FASCO
Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center at the University of Pennsylvania, discusses next-generation sequencing in thyroid cancer.
Advertisement
Clinical Pearls
Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center at the University of Pennsylvania, discusses next-generation sequencing in thyroid cancer.
- Data have been inconclusive regarding the appropriate use of next-generation sequencing in thyroid cancer.
- Next-generation sequencing may help identify higher-risk patients.
- In most patients, care is clear from their pathology.
- There is clearly a role for next-generation sequencing in the advanced setting.
Advertisement
Related to this article
Ravi Parikh, MD, MPP, discusses the future of oncology practice, including real-world data, patient engagement, emerging technologies, and policy priorities shaping cancer care.
Renuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
Renuka Iyer, MD, explains how NCCN is digitizing its guidelines with structured data to support AI tools, prior authorization, and point-of-care access.
Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
2
New ACS Guidelines Push for Earlier Prostate Cancer Screening
3
Survey Highlights NMIBC Care Challenges Among US Military Service, Veterans
4
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
5